To treat pelvic nodes or not? Greater testicular scatter does not explain the results of randomized trials

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages

  Roach III, Mark ^a   Lawton, Colleen A ^b   Chen, Josephine ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; TESTOSTERONE; ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; FOLLOW UP; HUMAN; LETTER; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; RADIATION SCATTERING; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TESTICULAR SCATTER; TESTOSTERONE BLOOD LEVEL; URETHROGRAPHY; WHOLE PELVIC RADIOTHERAPY; BLOOD; LYMPH NODE; MALE; NOTE; PELVIS; PROSTATE TUMOR; RADIATION EXPOSURE; TESTIS; TIME;

ANDROGEN ANTAGONISTS; HUMANS; LYMPH NODES; MALE; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTIS; TESTOSTERONE; TIME FACTORS;

EID: 77957561757     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.3010     Document Type: Letter

References (9)

1. King CR, Kapp DS: To treat pelvic nodes or not: Could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials? J Clin Oncol 27:6076-6078, 2009
2. Roach M 3rd, DeSilvio M, Lawton C, et al: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904-1911, 2003
3. Lawton CA, DeSilvio M, Roach M 3rd, et al: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646-655, 2007 (Pubitemid 47418390)
4. Roach M 3rd, DeSilvio M, Valicenti R, et al: Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66:647-653, 2006 (Pubitemid 44436716)
5. Taussky D, Bae K, Bahary JP, et al: Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. Urology 72:1125-1129, 2008
6. Roach M 3rd: Hormonal therapy and radiotherapy for localized prostate cancer: Who, where and how long? J Urol 170:S35-40; discussion S40-1, 2003
7. Roach M 3rd, Bae K, Lawton C, et al: Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys [epub ahead of print on April 7, 2010]
8. Taira AV, Merrick GS, Galbreath RW, et al: Pretreatment serum testosterone and androgen deprivation: Effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy. Int J Radiat Oncol Biol Phys 74:1143-1149, 2009
9. Roach M 3rd, Hanks G, Thames H, Jr., et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006